Clin2
NCT07580638Likely a fitNot yet recruiting

Adding Chiglitazar to SGLT-2 Inhibitors for Type 2 Diabetes

T2DM (Type 2 Diabetes Mellitus)

Part of Hormones & metabolism clinical trials.

This trial tests whether adding a new diabetes medication called chiglitazar to your current SGLT-2 inhibitor can help lower your blood sugar better. You may qualify if your blood sugar is still too high despite taking an SGLT-2 inhibitor, and this study could help find better ways to control your diabetes.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
3,550 people
Ages
18 years to 75 years
Study type
Observational

Who can take part

  • You are between 18 and 75 years old
  • You have been diagnosed with Type 2 Diabetes
  • You've been taking an SGLT-2 inhibitor (alone or with one other oral diabetes pill) for at least one month, but your blood sugar (HbA1c) is still at least 7.5%
  • You are not currently using insulin injections
  • You are not taking three or more different diabetes medications at once
  • You have not previously taken chiglitazar, and you are not currently taking thiazolidinediones (TZDs) or GLP-1 receptor agonists (such as Ozempic or Victoza)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07303803Recruiting· Phase 2
Testing Chiglitazar for fatty liver with diabetes

This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.

Beijing, Beijing Municipality
NCT07519265Not yet recruiting
Testing a new diabetes and heart health medication

This study compares two versions of a combination medication (chiglitazar and metformin) to ensure they work the same way in the body. Researchers are recruiting healthy volunteers to help determine if the new formulation is equivalent to the standard version.

NCT07244003Recruiting· Phase 4
Testing metformin with two newer diabetes drugs

This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.

Tianjin, Tianjin Municipality
NCT07511010Not yet recruiting· Phase 1
How food affects a new diabetes pill and its multiple doses

This trial tests how a new medication (chiglitazar combined with metformin extended-release) works in the body when taken with food and after multiple doses. Healthy volunteers are needed to help understand the drug's safety and how it is processed.

NCT07412015Not yet recruiting
Testing a new diabetes combination pill in healthy people

This study tests how well a new combination diabetes medication (chiglitazar/metformin) works in the body compared to taking the two drugs separately. It is for healthy volunteers and helps ensure the new pill is safe and effective.

NCT07558525Not yet recruiting
Chiglitazar with lifestyle changes for prediabetes

This trial tests whether a medication called Chiglitazar Sodium, combined with lifestyle changes like diet and exercise, can help reverse prediabetes (higher-than-normal blood sugar that isn't yet diabetes). If you have prediabetes, this study may help prevent you from developing type 2 diabetes.

Quanzhou, Fujian

Hear when a new T2DM (Type 2 Diabetes Mellitus) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.